155 related articles for article (PubMed ID: 33361584)
1. Identification of potential serum biomarkers for simultaneously classifying lung adenocarcinoma, squamous cell carcinoma and small cell carcinoma.
Yu J; Du F; Yang L; Chen L; He Y; Geng R; Wu L; Xie B
Cancer Biomark; 2021; 30(3):331-342. PubMed ID: 33361584
[TBL] [Abstract][Full Text] [Related]
2. The Landscape of Actionable Molecular Alterations in Immunomarker-Defined Large-Cell Carcinoma of the Lung.
Chan AW; Chau SL; Tong JH; Chow C; Kwan JSH; Chung LY; Lung RW; Tong CY; Tin EK; Law PP; Law WT; Ng CSH; Wan IYP; Mok TSK; To KF
J Thorac Oncol; 2019 Jul; 14(7):1213-1222. PubMed ID: 30978501
[TBL] [Abstract][Full Text] [Related]
3. Role of exposure to radon and silicosis on the cell type of lung carcinoma in German uranium miners.
Taeger D; Fritsch A; Wiethege T; Johnen G; Eisenmenger A; Wesch H; Ko Y; Stier S; Michael Muller K; Bruning T; Pesch B
Cancer; 2006 Feb; 106(4):881-9. PubMed ID: 16411224
[TBL] [Abstract][Full Text] [Related]
4. Integrated classification of lung tumors and cell lines by expression profiling.
Virtanen C; Ishikawa Y; Honjoh D; Kimura M; Shimane M; Miyoshi T; Nomura H; Jones MH
Proc Natl Acad Sci U S A; 2002 Sep; 99(19):12357-62. PubMed ID: 12218176
[TBL] [Abstract][Full Text] [Related]
5. [Value of combined detection of tumor markers for the prediction of small cell and non-small cell lung cancer].
Wu Y; Wu Y; Wang L; Qu L
Wei Sheng Yan Jiu; 2000 Jul; 29(4):213-5. PubMed ID: 12520921
[TBL] [Abstract][Full Text] [Related]
6. The important role of circulating CYFRA21-1 in metastasis diagnosis and prognostic value compared with carcinoembryonic antigen and neuron-specific enolase in lung cancer patients.
Zhang L; Liu D; Li L; Pu D; Zhou P; Jing Y; Yu H; Wang Y; Zhu Y; He Y; Li Y; Zhao S; Qiu Z; Li W
BMC Cancer; 2017 Feb; 17(1):96. PubMed ID: 28152979
[TBL] [Abstract][Full Text] [Related]
7. Serum tumour markers in lung cancer.
Hansen M
Scand J Clin Lab Invest Suppl; 1991; 206():93-101. PubMed ID: 1658919
[No Abstract] [Full Text] [Related]
8. The comparison between adenocarcinoma and squamous cell carcinoma in lung cancer patients.
Wang BY; Huang JY; Chen HC; Lin CH; Lin SH; Hung WH; Cheng YF
J Cancer Res Clin Oncol; 2020 Jan; 146(1):43-52. PubMed ID: 31705294
[TBL] [Abstract][Full Text] [Related]
9. [A clinical evaluation of the versatility of various tumor markers in diagnosing the primary carcinoma of the lung].
Shimabukuro Z
Nihon Ika Daigaku Zasshi; 1989 Jun; 56(3):281-93. PubMed ID: 2546967
[TBL] [Abstract][Full Text] [Related]
10. Thymidine kinase 1 combined with CEA, CYFRA21-1 and NSE improved its diagnostic value for lung cancer.
Jiang ZF; Wang M; Xu JL
Life Sci; 2018 Feb; 194():1-6. PubMed ID: 29247745
[TBL] [Abstract][Full Text] [Related]
11. Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients.
Kulpa J; Wójcik E; Reinfuss M; Kołodziejski L
Clin Chem; 2002 Nov; 48(11):1931-7. PubMed ID: 12406978
[TBL] [Abstract][Full Text] [Related]
12. Divergent genomic and epigenomic landscapes of lung cancer subtypes underscore the selection of different oncogenic pathways during tumor development.
Lockwood WW; Wilson IM; Coe BP; Chari R; Pikor LA; Thu KL; Solis LM; Nunez MI; Behrens C; Yee J; English J; Murray N; Tsao MS; Minna JD; Gazdar AF; Wistuba II; MacAulay CE; Lam S; Lam WL
PLoS One; 2012; 7(5):e37775. PubMed ID: 22629454
[TBL] [Abstract][Full Text] [Related]
13. Identification of potential erythrocyte phospholipid fatty acid biomarkers of advanced lung adenocarcinoma, squamous cell lung carcinoma, and small cell lung cancer.
Sánchez-Rodríguez P; Rodríguez MC; Sánchez-Yagüe J
Tumour Biol; 2015 Jul; 36(7):5687-98. PubMed ID: 25702090
[TBL] [Abstract][Full Text] [Related]
14. Decreased sphingomyelin (t34:1) is a candidate predictor for lung squamous cell carcinoma recurrence after radical surgery: a case-control study.
Takanashi Y; Funai K; Eto F; Mizuno K; Kawase A; Tao H; Kitamoto T; Takahashi Y; Sugimura H; Setou M; Kahyo T; Shiiya N
BMC Cancer; 2021 Nov; 21(1):1232. PubMed ID: 34789180
[TBL] [Abstract][Full Text] [Related]
15. Volume and Mass Doubling Time of Lung Adenocarcinoma according to WHO Histologic Classification.
Hong JH; Park S; Kim H; Goo JM; Park IK; Kang CH; Kim YT; Yoon SH
Korean J Radiol; 2021 Mar; 22(3):464-475. PubMed ID: 33169551
[TBL] [Abstract][Full Text] [Related]
16. [Squamous cell carcinoma, basaloid squamous cell carcinoma and adenosquamous carcinoma in the lung].
Vignaud JM
Ann Pathol; 2016 Jan; 36(1):15-23. PubMed ID: 26746368
[TBL] [Abstract][Full Text] [Related]
17. Detection and verification of coexisting diagnostic markers in plasma and serum of patients with non-small-cell lung cancer.
Yu M; Sun R; Zhao Y; Shao F; Zhu W; Aa J
Future Oncol; 2021 Nov; 17(32):4355-4369. PubMed ID: 34674559
[TBL] [Abstract][Full Text] [Related]
18. CT spectral parameters and serum tumour markers to differentiate histological types of cancer histology.
Jia Y; Xiao X; Sun Q; Jiang H
Clin Radiol; 2018 Dec; 73(12):1033-1040. PubMed ID: 30115364
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of serum tumor markers in patients with lung cancer.
Hatzakis KD; Froudarakis ME; Bouros D; Tzanakis N; Karkavitsas N; Siafakas NM
Respiration; 2002; 69(1):25-9. PubMed ID: 11844959
[TBL] [Abstract][Full Text] [Related]
20. Biomarkers in the lung cancer diagnosis: a clinical perspective.
Li X; Asmitananda T; Gao L; Gai D; Song Z; Zhang Y; Ren H; Yang T; Chen T; Chen M
Neoplasma; 2012; 59(5):500-7. PubMed ID: 22668014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
